Outlook 2024
Annual Industry Ranking And Forecast
Research & Development
New data show that European pharma innovation is being edged into third place by innovation coming from the US and the new powerhouse of research, China.
Investment In New Products: Looking Beyond The R&D Line
Johnson & Johnson and Roche lead the most recent Scrip 100 ranking for R&D spend, but a look beyond investment in internal development highlights a big year for Pfizer and Bristol Myer Squibb.
The Future Of Obesity
Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings.
Examining The Clinical Trials Landscape
In a post-pandemic world, the evolving landscape of clinical trials just got more complex. The year 2022 was one of many adjustments given the incidence of lower trial initiations. The health care industry endured the impacts of geopolitical conflicts, curbed growth in China and stagflation in major markets.
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Chapter sponsored by:
Navigating Innovation
To Deliver For Patients
Christelle Huguet,
Head of R&D at Ipsen, discusses how External Innovation is central to Ipsen’s R&D strategy and provides a spotlight on Rare Disease,
where the portfolio has seen strong movement in 2023.
Outlook 2024 e-Book
Download a PDF copy of the Outlook 2024 collection, including Scrip 100 league tables.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.